Advertisement
Advertisement
NATR
Nature's Sunshine Products Inc.
10.87
USDSponsored
+0.61
+5.95%
Nov 06, 15:59 UTC -5
Closed
After-Market
10.84
-0.03
-0.28%
Nature's Sunshine Products Inc. (NATR) Earnings
NATR Earnings Reports
Positive Surprise Ratio
NATR beat 13 of 20 last estimates.
65%
Next Report
Date of Next Report
Mar 08, 2027
Estimate for Q4 26 (Revenue/ EPS)
$124.86M
/$0.13
Implied change from Q3 26 (Revenue/ EPS)
+7.08%
/-7.14%
Implied change from Q4 25 (Revenue/ EPS)
+0.85%
/-56.67%
Nature's Sunshine Products Inc. earnings per share and revenue
On Nov 04, 2026, NATR reported earnings of 0.14 USD per share (EPS) for Q3 26, missing the estimate of 0.27 USD, resulting in a -48.21% surprise. Revenue reached 116.60 million, compared to an expected 132.10 million, with a -11.73% difference. The market reacted with a -20.09% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 0.13 USD, with revenue projected to reach 124.86 million USD, implying an decrease of -7.14% EPS, and increase of 7.08% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cronos Group Inc. Common Share
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
Aclaris Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.12
Surprise
+28.49%
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
Minerva Neurosciences, Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.12
Actual
$1.94
Surprise
+1,629.97%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.25
Surprise
-40.06%
ZOETIS INC.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.52
Actual
$1.75
Surprise
+14.64%
Dyne Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.92
Actual
-$1.06
Surprise
-15.57%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.38
Surprise
+1.04%
Aldeyra Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+37.43%
Lipocine Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.08
Surprise
+77.91%
FAQ
What were Nature's Sunshine Products Inc.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Nature's Sunshine Products Inc. reported EPS of $0.14, missing estimates by -48.21%, and revenue of $116.60M, -11.73% below expectations.
How did the market react to Nature's Sunshine Products Inc.'s Q3 2026 earnings?
The stock price moved down -20.09%, changed from $12.84 before the earnings release to $10.26 the day after.
When is Nature's Sunshine Products Inc. expected to report next?
The next earning report is scheduled for Mar 08, 2027.
What are the forecasts for Nature's Sunshine Products Inc.'s next earnings report?
Based on --
analysts, Nature's Sunshine Products Inc. is expected to report EPS of $0.13 and revenue of $124.86M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.